Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
In this trial we will evaluate and compare the efficacy and toxicity of oral topotecan with
intravenous docetaxel in the second-line treatment of patients with non-small cell lung
cancer.